Evolution of mitochondrial DNA content after planned interruption of HAART in HIV-infected pediatric patients

AIDS Research and Human Retroviruses

Volumn 26, Issue 9, 2010, Pages 1015-1018

  Noguera, Antoni ^a   Morén, Constanza ^b,c   Rovira, Núria ^a   Sànchez, Emília ^d   Garrabou, Glòria ^b,c   Nicolàs, Mireia ^b,c   Muñoz Almagro, Carmen ^e   Cardellach, Francesc ^b,c   Miró, Òscar ^b,c   Fortuny, Clàudia ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^d UNIVERSITAT RAMON LLULL   (Spain)

^e HOSPITAL SANT JOAN DE DÉU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; MITOCHONDRIAL DNA; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; FATIGUE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; PEDIATRICS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; VERTICAL TRANSMISSION; VIROLOGY; VIRUS LOAD; VIRUS REPLICATION; DRUG EFFECTS; HIV INFECTIONS; MOLECULAR EVOLUTION; PROSPECTIVE STUDY; TREATMENT WITHDRAWAL;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DNA, MITOCHONDRIAL; EVOLUTION, MOLECULAR; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROSPECTIVE STUDIES; WITHHOLDING TREATMENT;

EID: 77956365446     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0273     Document Type: Article

References (23)

1. Judd A, Doerholt K, Tookey PA, et al.: Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: Planning for teenage and adult care. Clin Infect Dis 2007;45:918-924.
2. Foster C and Lyall H: HIV and mitochondrial toxicity in children. J Antimicrob Chemother 2008;61:8-12.
3. McComsey GA and Leonard E: Metabolic complications of HIV therapy in children. AIDS 2004;18:1753-1768.
4. Division of AIDS table for grading the severity of adult and pediatric adverse events. December, 2004 [niaid.nih.gov web site]. Available at http://www3.niaid.nig.gov/research/resources/DAIDSClinRsrch/PDF/Safety/ DAIDSAEGrading Table.pdf. Accessed on September 1, 2009.
5. Noguera A, Fortuny C, Sanchez E, et al.: Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment. Pediatr Infect Dis J 2003;22:778-782.
6. Strategies for Management of Antiretroviral Therapy (SMART) Study Group; El-Sadr WM, Lundgren JD, Neaton JD, et al.: CD4-count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-2296.
7. Paediatric European Network for Treatment of AIDS: Response to planned treatment interruptions in HIV infection varies across childhood. AIDS 2010;24:231-241.
8. Desai N, Mathur M, and Weedon J: Lactate levels in children with HIV/AIDS on highly active antiretroviral therapy. AIDS 2003;17:1565-1568.
9. Boubaker K, Flepp M, Sudre P, et al.: Hyperlactatemia and antiretroviral therapy: The Swiss HIV Cohort Study. Clin Infect Dis 2001;33:1931-1937.
10. Rey C, Prieto S, Medina A, Pérez C, Concha A, and Menéndez S: Fatal lactic acidosis during antiretroviral therapy. Pediatr Crit Care Med 2003;4:485-487.
11. Scalfaro P, Chesaux JJ, Buchwalder PA, Biollaz J, and Micheli JL: Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment. Intensive Care Med 1998;24:247-250.
12. Blanche S, Tardieu M, Rustin P, et al.: Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084-1089.
13. Noguera A, Fortuny C, Muñoz-Almagro C, et al.: Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics 2004; 114:e598-603.
14. Saitoh A, Fenton T, Alvero C, Fletcher CV, and Spector SA: Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2007;51:4236-4242.
15. Cossarizza A, Pinti M, Moretti L, et al.: Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-positive children with highly active antiretroviral therapy-related lipodystrophy. J Infect Dis 2002;185: 299-305.
16. Rosso R, Nasi M, Di Biagio A, et al.: Effects of the change from stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: Studies on mitochondrial toxicity and thymic function. Pediatr Infect Dis J 008;27:17-21.
17. McComsey GA, Libutti DE, ORiordan M, et al.: Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection. Antivir Ther 2008;13:715-722.
18. Côté HC, Brumme ZL, Craib KJ, et al.: Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIVinfected patients. N Engl J Med 2002;346:811-820.
19. Mussini C, Pinti M, Bugarini R, et al.: Effect of treatment interruption monitored by CD4cell count on mitochondrial DNA content in HIV-infected patients: A prospective study. AIDS 2005;19:1627-1633.
20. Miró O, López S, Mart́nez E, et al.: Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals. Clin Infect Dis 2004;39:710-716.
21. Miura T, Goto M, Hosoya N, et al.: Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy. J Med Virol 2003;70:497-505.
22. Côté HC, Yip B, Asselin JJ, et al.: Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens. J Infect Dis 2003;187:1972-1976.
23. Urata M, Koga-Wada Y, Kayamori Y, Kang D: Platelet contamination causes large variation as well as overestimation of mitochondrial DNA content of peripheral blood mononuclear cells. Ann Clin Biochem 2008;45:513-514.